Page last updated: 2024-10-26

brl 42810 and HIV Wasting Syndrome

brl 42810 has been researched along with HIV Wasting Syndrome in 1 studies

HIV Wasting Syndrome: Involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhea or fatigue for more than 30 days in the absence of a defined cause other than HIV infection. A constant feature is major muscle wasting with scattered myofiber degeneration. A variety of etiologies, which vary among patients, contributes to this syndrome. (From Harrison's Principles of Internal Medicine, 13th ed, p1611).

Research Excerpts

ExcerptRelevanceReference
" Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy."3.70FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Highleyman, L1

Other Studies

1 other study available for brl 42810 and HIV Wasting Syndrome

ArticleYear
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1998

    Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D

1998